SEC Company Response from LARREA BIOSCIENCES CORP (CIK 0001175594) — Sep 26, 2005
LARREA BIOSCIENCES CORP (CIK 0001175594)
Date: Sept. 26, 2005 · CIK: 0001175594 · Accession: 0001144204-05-029839
AI Filing Summary & Sentiment
File numbers found in text: 000-50281
Show Raw Text
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>
LARREA BIOSCIENCES CORPORATION
4119 Montrose, Suite 230
Houston, TX 77006
September 26, 2005
Mr. Brian Bhandari
Securities and Exchange Commission
Washington, DC 20549
Re: Larrea Biosciences Corporation
File No. 000-50281
Dear Mr. Bhandari:
This progress report on your letters dated September 22 and September 2, 2005
follows our telephone conversation late last week.
We have changed auditors from LDMB in Vancouver to Bassie & Co in Houston, where
we have moved our executive and administrative functions. We will make one last
attempt to get LDMB to use alternative audit procedures that would enable them
to remove their inventory qualification on their recent audit report. Failing
that, Bassie & Co. will redo the audit as expeditiously as possible.
In the meantime, we will file an amended 8-K originally filed September 20, 2005
that will address the points raised in your September 22nd letter.
Further, we have finally received a response to our many inquiries from Madsen &
Associates and will file their response letter as an exhibit to an amended 8-K
relative to the 8-K originally filed on March 28, 2005.
We will defer filing amended 10-Qs for October 31, 2004 and January 31, 2005
until we have the results of the audit mentioned above. We anticipate having
these matters resolved by the end of October.
Very truly yours,
/s/ James A. Johnson
James A. Johnson
Chief Financial Officer
Cc: Peter Smetek, jr.
</TEXT>
</DOCUMENT>